Packed red blood cell (PRBC) transfusions are an important part of supportive treatment in oncology; however, when used frequently, they can be a result of transfusion-related iron overload. The aim of the study was to evaluate the role of ferritin as a non-specific marker of neoplastic growth and transfusion-related iron overload in children with lymphomas and solid tumors. We performed a longitudinal analysis of PRBC transfusions and changes in ferritin concentrations during oncological treatment of 88 children with lymphomas and solid tumors. A ferritin concentration above 500 ng/mL was diagnosed in 14.77% of patients at the moment of admission and 18.18% at the end of treatment. No differences were shown in serum ferritin in the context of tumor type-, sex-, and transfusion-related parameters. Those above the age of 10 demonstrated higher ferritin concentrations compared to subjects younger than 5 years of age. In addition, those over than 10 years old or above 30 kg in weight showed a tendency for better survival. All tested patients demonstrated highly significant correlations between ferritin at the 15th month of treatment or after therapy discontinuation and transfusion-related parameters. Interestingly, ferritin levels were found to lower back to the values before therapy shortly after its discontinuation. Transfusion parameters and ferritin levels had no influence on the survival of the studied cancer patients.
浓缩红细胞输注是肿瘤支持治疗的重要组成部分；然而，频繁使用可能导致输血相关性铁过载。本研究旨在评估铁蛋白作为非特异性标志物，在淋巴瘤和实体瘤患儿中反映肿瘤生长及输血相关性铁过载的作用。我们对88例淋巴瘤和实体瘤患儿在肿瘤治疗期间的浓缩红细胞输注情况及铁蛋白浓度变化进行了纵向分析。结果显示，入院时14.77%的患者及治疗结束时18.18%的患者出现铁蛋白浓度高于500 ng/mL的情况。在不同肿瘤类型、性别及输血相关参数背景下，血清铁蛋白水平未显示显著差异。与5岁以下患儿相比，10岁以上患儿表现出更高的铁蛋白浓度。此外，年龄超过10岁或体重超过30公斤的患儿显示出更好的生存趋势。所有受试患者在治疗第15个月或治疗终止后，其铁蛋白水平与输血相关参数均呈现高度显著相关性。值得注意的是，治疗终止后短期内铁蛋白水平即回落至治疗前水平。输血参数与铁蛋白水平对研究对象的生存率未产生显著影响。
肿瘤(癌症)患者之家